Developing medicinal cannabis producer AusCann has named an experienced pain medicine specialist as its chief medical adviser.
Subscribe now for unlimited access.
$0/
(min cost $0)
or signup to continue reading
AusCann, which has a supply agreement for cannabis resin with Tasmanian Alkaloids, recently announced the appointment of Marc Russo.
It said Dr Russo would lead the company's medical strategy, which included "medical education, clinical evidence generation and clinical insights as the company develops new product pipelines and intellectual property".
"AusCann has been advancing its medical outreach program, which provides doctors and healthcare practitioners access to cannabinoid medical resources."
The company said it would extend the program under Dr Russo's leadership to include peer to peer education, guidance for clinical evaluation and sharing of clinical best practice.
AusCann chief executive Ido Kanyon said: "Developing standardised products, generating clinical evidence and building medical acceptance will drive AusCann's value growth and result in better care for patients."
